Insider trades
Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.
- $1.5B bought by 340 insiders at 207 companies
- $3.2B sold by 266 insiders outside a trading plan
- $7.9B sold by 827 insiders under 10b5-1 plans
- 10 companies where two or more insiders bought (30 days)
Biggest buys
Past month, each insider's filings added up.
-
LENLennarBerkshire Hathaway Inc.10% owner, +1 joint filer$383M
-
CRBGCorebridge FinancialLife Insurance Co Nippon10% owner$225M
-
KODKodiak SciencesBaker Bros. Advisors LPDirector, +5 joint filers$157M
-
SAFXXCF GlobalEEME Energy SPV I, LLC10% owner$142M
-
GPIGroup 1 AutomotiveConifer Management, L.L.C.10% owner$97.8M
-
UUUUniversal Safety ProductsMilton C Ault IIIDirector$92.5M
-
GMEGameStopRyan CohenCEO$50.4M
-
BORRBorr DrillingTor Olav TroimDirector$43M
-
PAMPampa EnergiaMarcos Marcelo MindlinDirector$35.1M
-
GGRGogoroChung-Yao YinDirector$35.1M
Biggest sales
Past month, each insider's filings added up. Planned sales are marked.
-
IHTInnSuites Hospitality TrustJames F WirthCEO$4.2B
-
MDLNMedlineGIC Private Ltd10% owner, +2 joint filers$996M
-
ESTCElasticSteven SchuurmanDirector$323M
-
TALOTalos EnergyEmpresarial De Capitales S.a. De C.v. Control10% owner$253M
-
AVGOBroadcomHenry SamueliDirector$250M
-
THTarget HospitalityTDR Capital II Investments LP10% owner, +9 joint filers$202M
-
ANETArista NetworksJayshree UllalCEO$166M
-
KNTKKinetikISQ Global Fund II GP LLC10% owner, +4 joint filers$134M
-
CRWDCrowdStrikeBurt W. PodbereCFO$125M
-
NBISNebius GroupOphir NaveCOO$118M
Cluster buying
Companies where two or more insiders bought on the open market in the last 30 days, most buyers first
-
Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more
-
Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more
-
R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more
-
Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +1 more
-
Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more
-
John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more
-
Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more
-
Matthew G De Soto Director, Albert J. Evans Director, Kimberly J Brumbaugh Director, Theodore W Mowery Director, +1 more
-
Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO
-
Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director
OTLK insider trades
Every open-market buy and sale in OTLK, one row per filing, newest first
-
Robert Charles Jahr CEOOTLKOutlook TherapeuticsBuy— 151,515 shares New stakeTraded Aug 14 Filed Aug 14
-
Ghiath M. Sukhtian Director, +1 joint filerOTLKOutlook TherapeuticsBuy$2.5M 2,525,252 shares at $0.9900 +11% to stakeTraded Aug 12 Filed Aug 14
-
Lawrence A Kenyon CFOOTLKOutlook TherapeuticsBuy— 101,010 shares +1699% to stakeTraded Aug 14 Filed Aug 14
-
Faisal Ghiath Sukhtian DirectorOTLKOutlook TherapeuticsBuy$100K 95,398 shares at $1.05 +76% to stakeTraded Jul 29 Filed Jul 29
-
Yezan Munther Haddadin DirectorOTLKOutlook TherapeuticsBuy$24K 29,000 shares at $0.8300 +78% to stakeTraded Jun 2 Filed Jun 3
-
Ghiath M. Sukhtian Director, +1 joint filerOTLKOutlook TherapeuticsBuy$5M 8,539,709 shares at $0.5900 +63% to stakeTraded May 28 Filed Jun 1
-
Faisal Ghiath Sukhtian DirectorOTLKOutlook TherapeuticsBuy$50K 122,174 shares at $0.4100 +3593% to stakeTraded May 27 Filed May 27
-
Yezan Munther Haddadin DirectorOTLKOutlook TherapeuticsBuy$15K 34,000 shares at $0.4400 +1074% to stakeTraded May 26 Filed May 27
-
Randy H Thurman DirectorOTLKOutlook TherapeuticsBuy$2,145 5,000 shares at $0.4300 +843% to stakeTraded May 26 Filed May 27
-
Kurt J Hilzinger DirectorOTLKOutlook TherapeuticsBuy$177K 400,000 shares at $0.4400 +1691% to stakeTraded May 26 Filed May 27
About this data
- Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
- Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
- A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
- Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
- We cover the 4,839 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.